Novo Nordisk Amycretin diabetes Phase II Clinical Data Release
On November 25, 2025, Novo Nordisk announced that the GLP-1/Amylin double target agonist Amycretin had obtained positive data in the second phase of clinical treatment of diabetes. After 36 weeks of subcutaneous injection once a week, the weight loss was up to 14.5% (2.6% in the placebo group), 89.1% of patients' HbA1C was reduced to below 7%, and the HbA1c was reduced to 1.8% at the highest (calculated according to the completion of the treatment plan). The efficacy of daily oral Amycritin is slightly weaker, with a maximum weight loss of 10.1% (2.5% in the placebo group) after 36 weeks of treatment. 77.6% of patients experienced a decrease in HbA1c to below 7%, with a maximum HbA1c reduction of 1.5%.
Previously, Novo Nordisk disclosed phase 1b/2a clinical data of Amycritin treatment for obesity, with a weight loss of 22.0% after 36 weeks of treatment. The phase II clinical data of diabetes again verified the excellent efficacy of Amycretin, surpassing the combined treatment of GLP-1+Amylin (non head to head).
Xinda Biotech's application for high-dose marketing of 9mg Masidomide peptide has been accepted by CDE
On November 25, 2025, Xinda Biopharmaceutical Group (stock code: 01801 on the Hong Kong Stock Exchange), a biopharmaceutical company dedicated to the research, development, production, and sales of innovative drugs for major diseases such as tumors, autoimmune diseases, metabolism, cardiovascular diseases, and ophthalmology, announced today that the application for the long-term weight control of adult moderate to severe obesity patients with a high dose of 9mg of Xinermei @ (Masidu Peptide Injection, Glucagon [GCG]/Glucagon like Peptide-1 [GLP-1] Dual Receptor agonist) has been accepted by the Drug Evaluation Center (CDE) of the National Medical Products Administration (NMPA) of China. Mashdu peptide is expected to provide a potent and safe new treatment option for the Chinese population with moderate to severe obesity, in addition to weight loss surgery.
This listing application is based on the excellent results of the Phase I registered clinical study GLORY-2 (NCT06164873) conducted on the moderate to severe obesity population in China using Mashdu Peptide 9mg. The study recently achieved the primary endpoint and all key secondary endpoints.
During the treatment period, the average weight of the subjects in the Masidomide group continued to decrease and did not reach the plateau at week 60. At week 60, the average weight loss of subjects in the 9mg group of Masidogrel was 18.55%, while that in the placebo group was 3.02%; 44.0% of the subjects in the 9mg group of Masidomide achieved a weight loss of 20% or more, while the proportion in the placebo group was 2.6% (both P values were less than 0.0001).
The results of the key secondary endpoint of the study showed that among the subjects without type 2 diabetes, at the 60th week, the average weight loss of the subjects in the 9 mg group was 20.08%, and that in the placebo group was 2.81%; 48.7% of the subjects in the 9mg group of Masidomide achieved a weight loss of 20% or more, while the proportion in the placebo group was 3.1% (both P values were less than 0.0001).
In addition, the study also observed that 9mg of Masidogrel can significantly reduce the liver fat content of some subjects, with a decrease of 71.9% compared to the baseline average percentage. It also showed significant comprehensive improvements in key cardiovascular metabolic indicators such as blood pressure, blood lipids, blood uric acid, and waist circumference.
The safety of Masidu peptide 9mg is good, and no new safety signals have been found.
Detailed data regarding the achievement of all endpoints in GLORY-2 research is planned to be published in future international academic journals or conferences.